AI assistant
BIOGEN INC. — Director's Dealing 2017
May 1, 2017
30291_dirs_2017-05-01_692b1a97-5757-4c85-b3bc-7e6b25788347.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2017-04-27
Reporting Person: DENNER ALEXANDER J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-04-27 | Common Stock | P | 15000 | $278.58 | Acquired | 325000 | Indirect |
| 2017-04-27 | Common Stock | P | 58858 | $278.48 | Acquired | 383858 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 8974 | Direct |
Footnotes
F1: On April 27, 2017, Sarissa Capital Domestic Fund LP, a Delaware limited partnership ("Sarissa Domestic"), purchased an aggregate of 73,858 shares of common stock of Biogen Inc.
F2: Includes (i) 205,142 shares beneficially owned by Sarissa Domestic and (ii) 119,858 shares beneficially owned by Sarissa Capital Offshore Master Fund LP, a Cayman Island exempted limited partnership ("Sarissa Offshore" and together with Sarissa Domestic, the "Sarissa Funds"). Sarissa Capital Management GP LLC, a Delaware limited liability company ("Sarissa Capital GP"), is the general partner of Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), the investment advisor to the Sarissa Funds.
F3: Alexander Denner is the Chief Investment Officer of Sarissa Capital and the managing member of Sarissa Capital GP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Dr. Denner disclaims beneficial ownerhip of these shares except to the extent of his pecuniary interest therein.
F4: Includes (i) 264,000 shares beneficially owned by Sarissa Domestic and (ii) 119,858 shares beneficially owned by Sarissa Offshore.
F5: On 6/8/16 an RSU was awarded for 1,060 shares. This award was adjusted to 1,084 shares pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017.